DATA GRAPHICS | Data Byte
The market cap performance of the 2018 class of U.S. IPOs
At year-end, twice as many of the companies had lost value since their IPOs than gained value
April 5, 2023 8:29 PM UTC
Five years after listing on U.S. exchanges, nearly three quarters of the U.S. IPO class of 2018 remains active and publicly listed. The prolonged bear market has taken a toll on company valuations, however. At the end of 2022, the group’s median market cap performance since going public was -59%.
In 2018, 62 biotechs went public on U.S. exchanges, 45 (73%) of which remained active as of March 31, according to BioCentury’s BCIQ database. ...